Equity - Additional Information (Details) $ / shares in Units, $ in Thousands					12 Months Ended
	Oct. 15, 2021 shares	May 24, 2021 shares	May 23, 2021	Mar. 28, 2021 shares	Dec. 31, 2022 USD ($) D $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 $ / shares shares	Mar. 31, 2020 shares
Stockholders Equity [Line Items]
Common stock, shares authorized					500,000,000	500,000,000
Common stock, par value | $ / shares					$ 0.001	$ 0.001
Shares of common stock sold					49,605
Number of shares issued upon exercise of warrants					49,605	516,025
Issuance of common stock for exercise of warrants and Unit Purchase Options | $						$ 16,700
Contingently issuable Earnout Shares Excluded from EPS computation						1,044,453
Common stock issued for consulting services (in shares)						4,834,045
Non-cash consulting expense | $						$ 53,837
Common stock and warrants issued in private placement, net of issuance costs (in shares)					7,824,727
Common stock issued | $						$ 9,624
Proceeds from sale of common stock | $					$ 100
Awarded to employees as bonus for services provided					1,844,640	892,224
Compensation expenses | $					$ 3,628	$ 7,785
Loss on settlement of accounts payable | $						$ (121)
Preferred stock, shares authorized					50,000,000	50,000,000
Preferred stock, shares issued					0	0
Preferred stock, par value | $ / shares					$ 0.001	$ 0.001
Number of shares outstanding					0	0
Warrant issued					8,215,963	6,193,449
Warrants, exercise price per share | $ / shares					$ 6.49	$ 9.09	$ 1.09
Gross proceeds from exercise of warrants | $						$ 100
Proceeds from exercise of warrant | $						16,699
Number of shares issued upon exercise of warrants | $					$ 10	16,699
Net impact to additional paid-in capital | $						$ 60,852
Number of outstanding warrants					16,484,923	9,305,790	3,075,470
Change in fair value of the warrants | $					$ (255)	$ (1,692)
Unamortized compensation costs | $					2,200
Substitute Warrants
Stockholders Equity [Line Items]
Warrants, exercise price per share | $ / shares						$ 2.45
Warrants exercised						4,909,066
Incremental compensation costs | $					$ 2,300
Public Warrants
Stockholders Equity [Line Items]
Warrants, exercise price per share | $ / shares					$ 11.50
Number of outstanding warrants					3,450,000
Number of shares per warrant					1
Warrants expiration term					5 years
Redemption price per warrant (in dollars per share) | $ / shares					$ 0.01
Minimum threshold written notice period for redemption of warrants					30 days
Stock price trigger for redemption of warrants (in dollars per share) | $ / shares					$ 21.00
Threshold trading days for redemption of warrants | D					20
Redemption period | D					30
Placement Warrants
Stockholders Equity [Line Items]
Number of outstanding warrants					136,250
GEM Warrant
Stockholders Equity [Line Items]
Number of shares issued upon exercise of warrants				1,496,216
Merger agreement
Stockholders Equity [Line Items]
Merger and PIPE Financing shares - common stock						3,729,730
Exchange Ratio		3.16	4.96
Merger agreement | Stockholders of NeuroRx
Stockholders Equity [Line Items]
Exchange Ratio		3.16	4.96		3.16
VaccineCo
Stockholders Equity [Line Items]
Merger and PIPE Financing shares - common stock	4,000,000
Convertible Series A Preferred Stock [Member]
Stockholders Equity [Line Items]
Convertible preferred stock, liquidation preference per share | $ / shares					$ 1.00
Convertible Series A Preferred Stock [Member] | Legacy NeuroRx Warrants
Stockholders Equity [Line Items]
Preferred stock, shares authorized					1,000,000
Preferred stock, par value | $ / shares					$ 0.001
Convertible Series B-1 Preferred Stock [Member]
Stockholders Equity [Line Items]
Convertible preferred stock, liquidation preference per share | $ / shares					$ 7.58
Convertible Series B-1 Preferred Stock [Member] | Legacy NeuroRx Warrants
Stockholders Equity [Line Items]
Preferred stock, shares authorized					1,050,695
Convertible Series B-1A Preferred Stock [Member]
Stockholders Equity [Line Items]
Convertible preferred stock, liquidation preference per share | $ / shares					$ 6.82
Convertible Series B-1A Preferred Stock [Member] | Legacy NeuroRx Warrants
Stockholders Equity [Line Items]
Preferred stock, shares authorized					316,848
General and Administrative Expense [Member]
Stockholders Equity [Line Items]
Non-cash consulting expense | $						$ 53,800
Compensation expenses | $					$ 3,002	$ 6,500
Common Stock
Stockholders Equity [Line Items]
Issuance of common stock for exercise of warrants and Unit Purchase Options (in shares)						3,830,586
Number of shares issued upon exercise of warrants						565,630
Common stock and warrants issued in private placement, net of issuance costs (in shares)						3,642,727
Proceeds from sale of common stock | $						$ 37,000
Awarded to employees as bonus for services provided					200,000
Common Stock | General and Administrative Expense [Member]
Stockholders Equity [Line Items]
Compensation expenses | $						$ 4,800
Legacy NeuroRx Preferred Stock | Stockholders of NeuroRx
Stockholders Equity [Line Items]
Exchange Ratio		3.16
Legacy NeuroRx Preferred Stock | Convertible Series A Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred stock, conversion basis					one share of common stock for each preferred share
Number of shares outstanding		2,367,543
Shares issued upon conversion		7,480,836
Legacy NeuroRx Preferred Stock | Convertible Series B-2 Preferred Stock [Member]
Stockholders Equity [Line Items]
Preferred stock, shares authorized							100,000
Preferred stock, shares issued							0.001	4,167
Preferred stock, conversion basis							one share of common stock for each share of B-2 Preferred Stock
Convertible preferred stock, liquidation preference per share | $ / shares							$ 12.00
Number of shares outstanding		4,167
Shares issued upon conversion		13,168